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Abstract 
This article proposes solid-like systems from sunflower oil structured with a fibrillar network 
built by the assembly of 12-hydroxystearic acid (12-HSA), a gelator molecule for an oil phase. 
The resulting organogels were studied as oral controlled release formulations for a lipophilic 
drug, Efavirenz (EFV), dissolved in the oil. The effects of the gelator concentration on the 
thermal properties of the organogels were studied by Differential Scanning Calorimetry (DSC) 
and showed that drug incorporation did not change the sol-gel-sol transitions. The erosion 
and drug release kinetics from organogels under conventional (filling gelatin capsules) or 
multiparticulate (beads obtained by prilling) dosage forms were measured in simulated gastric 
and intestinal fluids. EFV release profiles were analyzed using model-dependent (curve-fitting) 
and independent approaches (Dissolution Efficiency DE). Korsmeyer-Peppas was the best 
fitting release kinetic model based on the goodness of fit, revealing a release mechanism from 
organogels loaded with EFV different from the simple drug diffusion release mechanism 
obtained from oily formulations. From organogels, EFV probably diffuses through an outer gel 
layer that erodes releasing oil droplets containing dissolved EFV into the aqueous medium . 
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Introduction 
Interest in lipid-based drug delivery has developed over the past 
15 years, largely driven by the growing need for novel drug 
delivery systems to deal with the vast majority of the new 
chemical entities (NCE) that have poor solubility, or permeability 
or to improve the delivery of existing drugs 1•
The diversity of commercialized lipid excipients (e.g. fatty 
acids, glycerides, polyoxyethylene glycols derivatives, ethoxy- 
lated glycerides and polyalcohol fatty acid esters) has created a 
large platform for lipid-based formulation design. Depending on 
the choice of lipid excipients and formulation techniques, it is 
possible to obtain a variety of systems in the forms of emulsions, 
microemulsion s, micelles, liquid crystalline particles, solid lipid 
particles and various self-emulsifying systems. 
Successfully marketed oral lipid-based drug  products,  cur- 
rently conceming S4% of the global pharmaceutical market, are 
mostly formulated as bulk liquid solutions or liquid-filled gelatin 
capsules2• Clinical translation of novel lipid-based formulations is 
clearly related to the rate of discovery of pipeline drugs exhibiting 
poor aqueous solubility, which is predicted  to increase from 30% 
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to 70%3. Major barriers for attaining full commercial potential for 
lipid-based formulations are associated with challenges in their 
physical stability, non-ideal drug encapsulation and unpredictable 
delivery performance. 
The primary mechanism of action by which a lipid formulation 
leads to improved bioavailability is usually avoidance of the slow 
dissolution process that limits the bioavailability of hydrophobie 
drugs from solid dosage forms. A formulation keeping the drug in 
a dissolved state throughout its transit in the gastrointestinal tract 
(Gl tract) appears preferable. In this context, a gel vehicle and 
especially an organogel could be useful to improve the bioavail- 
ability of a hydrophobie drug. Ingeneral, a gel may be defined as 
a semi-solid formulation having an external solvent phase, apolar 
(organogel) or polar (hydrogel) immobilized by a 3D-network 
scaffold. Organogels may be regarded as bi-continuous systems 
consisting of a gelator and an apolar solvent. The gelators may 
undergo physical or chemical interactions so as to form self- 
assembled entangled fibrous structures leading to the formation of 
a three-dimensional scaffold. The 3D-networked structure, hence 
formed, entraps and immobilizes the apolar phase. 
In the last 20 years, there has been an explosive growth in 
research on organogels, and on publications related on them4- 11 as 
another category of lipid system. Most of these publications 
report the discovery and/or the synthesis of new organogelators, 
the properties of organogels including the gel microstructures 
and the manner in which the gelator molecules could be arranged 
in 3-D network structures. The large diversity in terms of the 
possible microscopie structures available for organogels origi- 
nated the interest for applications of these soft materials in the 
petrochemical industry for gelling flammable solvents for storage 
and transport 12, in the food industry for structuring edible oils13,
in the cosmetic field14 and more recently as part of pharmaceut- 
ical drug delivery systems. As far as drug delivery is concerned, 
organogels  appear  as  suitable  carriers for lipophilic  drugs. 
Consequently, in recent years, the possibility of using organogels 
as drug delivery vehicles has been explored for parenteral 9 and 
transdermal delivery8·10·". Nevertheless, so far, only few studies 
have been carried out on oral drug delivery 15-17. 
Starting from these considerations, this study proposes the 
application of organogels to integrate attractive and nove! lipid- 
based delivery systems for controlled release of a hydrophobie 
drug, Efavirenz (EFV), via oral administration. EFV is a non- 
nucleoside reverse transcriptase inhibitor, used for the treatment 
of the human immunodeficiency virus (HIV). EFV is a molecule 
of class IIof the biopharmaceutical class system18 that presents 
low aqueous solubility (4 µg/ml)19 and high permeability. 
Efavirenz (EFV) is a first-line anti-HIV drug largely used as a 
non-nucleoside reverse transcriptase inhibitor as part of antiretro- 
viral therapies. EFV as active pharmaceutical ingredient (APT) is 
commercially available as micronized powder. Sorne papers20-22 
have been published focusing on EFV innovative solid forms, but 
there is no clear evidence of solubility or dissolution improve- 
ment. Other studies23-27 have led to an amorphous system that 
was inherently unstable, could recrystallize and had low physical 
stability. Organogels for oral administration of EFV could 
represent an innovative drug delivery system, particularly under 
multiparticul ate forms. 
Among the different physical methods available to obtain 
multiparticulate forms, such as spray drying, fluid bed coating or 
extrusion, prilling is able to produce microparticles or beads 
(prills) with very narrow dimensional range and high encapsula- 
tion efficiency. These beads are produced by breaking apart a 
laminar jet of molten organogel into a row of monosized drops by 
means of a vibrating nozzle device. The aim of this study was also 
to show that prilling technique could be used as a simple method 
to prepare organogel beads with narrow particle size distribution 
loaded with Efavirenz, as multiparticulate dosage forms. 
Multiparticulate dosage forms are known to overcome the poor 
and variable GI tract absorption of drugs and have shown the 
ability to reduce or eliminate the influence of food on 
bioavailability 28.
ln view of the above, the control release of EFV from 
sunflower oil-based organogel structured with 12-hydroxystearic 
acid (12-HSA) as gelator has been studied. The 12-HSA was 
chosen because it is one of the most studied molecular gelators for 
cosmetics29 and more recently for food 17 and drug delivery 
applications 15 in part due to its inexpensive cost, versatility in 
gelling numerous solvents30 and safety29. The effect of different 
parameters (gelator concentration, temperature of the gel forma- 
tion, EFV loading, composition of the release media) on the 
thermal properties of the gels and drug release kinetics was 
investigated. The erosion rate was also investigated for the gel 
capsules. 
Materials and methods 
Materials 
A food grade sunflower oil (density of 0.92 g/mL) provided by a 
local supplier was chosen as the vegetable oil for organogel 
preparation. Sunflower oil is mainly composed of linoleic acid 
(60--703w/w), but it also contains oleic acid (14-353w/w), 
palmitic   acid   (3-103w/w)   and   stearic   acid   (1-103w/w)31.
12-Hydroxystearic   acid    (12-HSA    853,   C18H3603,     MW 
300.48 g/mol) was purchased  from   Alfa  Aesar  (France)  and 
used as gelling agent. Efavirenz (EFV)  was  obtained  from 
Cristalia S.A. (!tapira, Brazil). Acetonitrile used in solubility, 
pepsin and pancreatin used in the erosion/drug  release  studies 
were supplied by Sigma-Aldrich (France). Sodium dodecyl sulfate 
(SDS)  was supplied by VWR  (Prolabo, France). 
Methods 
Drug solubility  in gel and oil phases 
EFV soluhility in molten organogels. The enthalpies of solution 
of EFV in molten organogels were carried out  isothermally 
(90.0 ± 0.5 °C) using a heat flux in a Calvet calorimeter model- 
C80 (Setaram, France) equipped with two mixture cells, one for 
reference. Each ceII has an upper and lower compartment 
separated by a displaceable lid that allows the connection of 
compartments during the analysis. The sample cell was filled with 
accurately weighed amount of drug (30, 60, 70, 75 and 80mgEFv/ 
g0rganoge1) in the lower compartment and 1g of organogel in the 
upper compartment. After thermal stabilization, the vesse! was 
rotated by 180° several times, which displaces the lid between the 
drug and solution leading to their mixing. The signal was 
automatically recorded on the strip chart recorder. Experiments 
were conducted in duplicate. 
EFV soluhility in sunjlower oil. The solubility of Efavirenz in 
sunflower oil was determined at 37 ± 1 °C by adding excess drug 
(5 g) to the oil (50 g). The suspensions were equilibrated in a 
constant temperature shaking water bath during 24, 48 and 72 h. 
An aliquot of the filtered samples ( 1 mL) was transferred to a 
volumetric flask for appropriate dilution with acetonitrile (ACN); 
subsequently, 1mL of the resultant solution was diluted with the 
mobile phase acetonitrile: acetate buffer (60:40) and analyzed by 
High Performance Liquid Chromatography (HPLC) (LaChrom 
Elite, Hitachi) to  determine the amount of dissolved EFV. The 
HPLC   was   equipped   with    reversed-phase    column    C18, 
250 x 4.6 mm, 5 µm (Kinetex™ - Phenomenex, France) and the 
HPLC column operating conditions  were  optimized  [mobile 
phase ACN: acetate buffer (60:40), 1.0mL/min flow rate, volume 
injection of 40 µL, UV-detector 252 nm]. Experiments were 
conducted  in triplicate. 
Thermal analys is 
12-HSA was added to sunflower oil over a range of compositions 
(2-303 w/w). Samples were prepared by dissolving the weighed 
solid organogelator in a weighed amount of liquid oil at 85 °C 
under stirring (300rpm). The heated solutions were subsequently 
cooled to room temperature (25 °C) and stored at this temperature 
for further analysis. For the formulations including EFV in the 
organogel (30 or 60 mg EFV/g0rganoge1), both EFV and 12-HSA 
were weighed and added to sunflower oil. The mixture was then 
heated at 85 °C with gentle stirring during 30 min to melt the 
organogel and dissolve EFV. The heated solutions were subse- 
quently cooled to room temperature and stored under the same 
conditions for further analysis. AU concentrations are expressed as 
a weight percentage (wt3). 
Thermal properties  of organogels, unloaded or loaded with 
EFV, were determined by Differential Scanning Calorimetry 
(DSC) using a FRS5 calorimeter (Mettler Toledo, France). 
Samples (5-10mg) were hermetically sealed in  aluminum 
standard pans. Temperature was heated and cooled at a rate of 
3 °C/min from 15 to 85 °C for two cycles. Before the second 
cycle, the system was kept al 15°C for 20 min. A nitrogen gas 
purge was used at 20 mL/min. Melting (Tm) and crystallization 
(Tc) points were determined from DSC data (onset, peak and end 
temperatures as well as the associated specific enthalpies). 
Erosion and release kinetics from  organogel  in a conventional 
dosage form  (cylindrical shape) 
The erosion mode of the delivery system is one of the factors 
controlling drug release. In order to understand the release 
kinetics in relation to their weight changes, both erosion rate and 
release rate were determined and correlated. 
Molten organogels loaded with EFV were solidified in hard 
shell gelatin capsules (size #00: i.e. 0.95 mL of capacity volume; 
length of 23.3mm and diameter of 8.2mm) at 25 or 5 °C. The 
dissolution of gelatin capsules after five minutes of contact with 
the dissolution media did not affect erosion nor release rate. Two 
gelator concentrations were used (5 and 20 wt% of 12-HSA). 
Erosion and drug release were measured from the organogels in a 
SOTAX AT7 (Switzerland) dissolution bath at 37 ± 0.5 °C. The 
organogels capsules were weighed, placed in a USP dissolution 
basket and immersed in 500 mL dissolution media at 50rpm. The 
simulated gastric solution comprised pepsin (800 U/L of enzyme 
activity) dissolved in 0.1 N hydrochloric acid (pH 1.2) and the 
simulated intestinal solution included pancreatin (1750 U/L of 
protease activity and 140 U/L of lipase activity)32 dissolved in 
phosphate-buffered saline (pH 6.8). Both solutions contained 
1.0wt% SDS according to dissolution monograph of  Efavirenz. 
The organogels were removed from the test solution (1, 2, 3, 4, 6 
and 8 h after starting) and dried under ambient conditions during 
24 h. Determination s were performed  in duplicate. 
Organogel erosion was determined by difference in weight, 
taking the amount of the drug release into account. Percentage of 
organogel erosion (E) at time t was calculated from Equation (1). 
E(%) = ( mo - m, - mEFVreleased ) X lOO (l) 
mo 
Where m0 is the initial weight of the organogel, m1 the weight of 
the organogel subjected to erosion for time t and mEFVreleased the 
weight of EFV released at time t. 
When the organogel was removed from the test solution, 5 mL 
of the medium was also withdrawn from the incubation vesse!. 
The amounts of EFV dissolved were determined by HPLC 
(LaChrom Elite, Hitachi), utilizing a reversed-phase column Cl8, 
250 x 4.6 mm, 5 µm (Kinetex™ - Phenomenex, France); UV- 
detector 252 nm; 1.0mL/min flow rate; 40 µL volume injection 
and mobile phase ACN: acetate buffer (60:40). 
Methods used ta compare EFV release profiles from  the 
cylindrical  organogels 
Efavirenz (EFV) release profiles were analyzed using model- 
dependent (curve-fitting) and independent approaches 
(Dissolution Efficiency - DE). The free open source software 
KinetDS®33 was used to fit the release curves to the Korsmeyer- 
Peppas, Weibull  and Hixson-Crowell mathematical models 
[Equations (2-4), respectively, Table 1). The accuracy and 
prediction ability of these models were compared by calculation 
of coefficient of determination (R2), AIC (Akaikes's information 
criterion) and RMSE (root mean square error). 
The dissolution (or release) efficiency (DE), calculated by 
KinetDS® according to Equation (8) (Table 1), is a model- 
independent parameter that was also used to evaluate the EFV 
release performance under different formulations and test condi- 
tions. The differences for DE were statistically examined by one- 
way analysis of variance (ANOVA) followed by  Tukey test, in 
order to find the source of difference (p<0.05). ln this method, 
DE  (n =2) was the dependent variable, and Formulation  was the 
factor. The calculations were performed using the  software 
Statistica version 12.0 (Data Analysis Software system, StatSoft, 
Inc., Tulsa, OK). Throughout the study, p ::;0.05 was used as the 
criterion  to assess statistical  significance. 
Organogel beads for  drug delivery purpose 
Preparation method. Before beads production, the organogel 
formulation was preliminary selected. The concentration of 12- 
HSA was fixed at 20 wt% and the drug loading at 60 mg/g, an 
interesting composition for controlled drug release. Blank 
organogels (without drug) were also prepared under the same 
conditions for comparison. Organogel beads were generated using 
prilling equipment (Spherisator M, BRACE - GmbH, Germany). 
After melting 12-HSA in sunflower oil at 90°C, EFV was added 
to the melt under stirring up to its complete dissolution in the 
molten matrix. By applying air pressure (50 mbar), the mixture 
was  extruded  towards  a thermostated nozzle  (inner diameter: 
0.4 mm). The extruded liquid jet was broken up into droplets of 
equal size by the application of a vibrational frequency (250 Hz). 
The droplets were allowed to form and fall into a thermostated 
vesse! containing water at 25 °C. The distance between the nozzle 
and the collector bath was adjusted  to  90 mm.  A  surfactant 
(0.2 wt% Tween-20) was added into the collector bath to prevent 
the formation of bead aggregates. The beads were collected 
immediately, rinsed thoroughly with distilled water and then 
stored in dry atmosphere  at ambient temperature until further 
experiments. 
Characterization  methods 
Bead size  and shape. Beads were observed by optical micros- 
copy (OM) and scanning electron microscopy (SEM). The OM was 
performed by numerical microscope (Keyence VHX-5000, France) 
equipped with objective-glass Z20 and ZlOO. Concerning SEM, a 
XL30 ESEM- FEG equipment (Philips, USA) was utilized . At least 
1OO beads were analyzed from each batch. An average value for ail 
beads has been calculated as the mean particle size. 
Raman microscopie mapping. To further characterize the beads, 
complementary Raman analyzes were undertaken focusing on the 
evaluation of the spatial distribution of the components within the 
gel beads. Raman microscopie mapping was performed using the 
Alpha 300AR Confocal Raman-AFM microscope (Witec, 
Germany) equipped with a double laser Nd:Y AG at a wavelength 
of 532 nm. Cross-sections of beads were scanned by a 50 x long 
working distance objective lens, which allowed 432 nm of lateral 
resolution and 1320 nm of axial resolution. Ail spectra were 
acquired using an exposure time of 10s and a step size of 0.2 µm. 
The area mapped was approximately 15 µm x 30 µm. The result- 
ing images provide information about the distribution of EFV 
within the organogel beads. 
Drug release studies from  organogel beads 
Dissolution profile of the organogel beads generated by prilling, 
composed with 20 wt% of 12-HSA and loaded with 60 mg/g of 
Efavirenz was performed using an USP4 apparatus (Sotax CH- 
4008, Switzerland) equipped with three flow-through cells. 
Twenty beads were placed into each cell operating at a flow 
rate set of 16mL/min in a closed circuit. In order to simulate the 
GI tract, two dissolution media were successively used according 
to Pharmacopeia recommendations (2 h at pH 1.2 and then 8 h at 
pH 6.8). About 1wt% SDS was added in the media as previously 
described. According to the literature, the equilibrium concentra- 
tion of the drug in simulated gastrointestinal fluid containing 
l wt%   is   close   to   2.5 mg/g,01ution    at   37 °C34.    The   drug 
Table 1. Dependent and independent kinetic models applied to analyze the drug release 
data. Approach Method 
Model-dependent Korsmeyer-Peppas Mt = KKP.t"   (2) 
Equations 
Weibull 
Hixson-Crowell 
Higuchi 
Mt  = 1-exp(-( •Ti)b) (3) 
(1 -Mt/Mo) 113= KHc.t     (4) 
Mt = KHi.t05  NE(5) 
Best mode/ criteria RM.SE = L.,'·=-' (yiobs-yipred)
2   (6) 
n 
AIC = 2k + n.[zn (   (yiobs -yipred ) 2) ] (7)
Model-lndependent Dissolution efficiency (DE) DE = ( fMi Mtdt) x 100   (8) 
trnax .t 
Mt: amount of drug released in time t. 
Mo: initial amount of drug in the dosage form. 
KHi is the release constant in Higuchi mode!. 
KHc is the release constant in Hixson-Crowell mode!. 
KKP is the release constant incorporating structural and geometric characteristics of the drug-dosage for; n is the diffusional exponent indicating the 
drug-re ease mechanism. 
Mtmax = maximum amount of drug released (=100%). 
N = number of time points. 
Ti = lag time before the onset of the release process (in most cases will be zero). 
a = time scale of the process. 
b = shape parameter. 
concentration used in the dissolution tests was 0.04 mg/gsotution·  
Samples were withdrawn  at predefined  time intervals up to  10h 
2.5 ------------------- 
and directly analyzed. The amount of drug released at each time 
point was determined by the previously described HPLC-UV 
method.  Ali  experiments  were performed  in triplicate. 
The free open source software KinetDS®25 was used to fit the 
release curves to the Korsmeyer-Peppas, Weibull, Hixson-Crowell 
and  Higuchi  mathematical  models  [Equations  (2-5), Table  l]. 
The accuracy and prediction ability of these models were compared 
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Results and discussion 
Drug solubility in molten organogels 
Organogels were prepared for prilling at 90 °C. The determination 
of the drug solubility in the molten organogel (for the highest 
organogelator concentration tested) was necessary to ensure the 
complete dissolution of the drug in the molten organogel and 
prevent nozzle clogging during prilling. 
Solution calorimetry measured the heat change generated from 
the dissolution of the solid EFV  by the molten organogel 
constituted of sunflower oil and 20 wt% of 12-HSA. The creation 
of a saturated solution at 90 °C involved dissolving the  solute 
(EFV) up to the maximum and constant concentration that also 
corresponds to a constant value of heat of solution. As shown in 
Figure 1, incremental amounts of EFV added to the molten 
organogel resulted  in a straight line increase in the magnitude of 
the heat  of solution until a plateau was reached when the 
concentration of the solute equaled the saturation point. From 
Figure 1, the EFV mass where the two straight lines cross 
corresponds to the amount of solute that saturates the solvent 
contents in the vesse!. The solubility value corresponds to 75 mg/g 
for EFV in the molten organogel at 90 °C. From these results, we 
choose to work with a concentration below the saturation (30 and 
60 mg of EFV per gram of organogel). 
0 20 40 60 80 100 
Efavirenz added mass, mg/g 
Figure 1. Enthalpy of dissolution of EFV in molten organogel comprising 
12-HSA (20 wt%) and sunflower oil at 90 °C. Means with error bars for 
two experiments (n = 2) are shown. 
It is also important at this stage to keep in rnind the organogel 
concept, in which oil is entrapped in a network self-assembly of 
the gelator molecules creating a gel. In this study, sunflower oil is 
entrapped in the self-assembled fibrillar networks of 12-HSA. The 
aim is to entrap EFV amounts smaller than its solubility lirnits at 
37 °C in the oil phase in order to keep the drug always dissolved 
when exposed to the release medium. This condition  is achieved 
for the EFV concentrations equal or lower than 60 mg per gram of 
organogel containing 20% 12-HSA (corresponding to 75 mg per 
gram of sunflower oil), since the equilibrium concentration 
determined experimentally after 72 h is equal to 79.8 ± 0.6 mg of 
EFV per gram of sunflower oil as shown in Table 2. 
Thermal analysis 
The effects of the gelator concentration and the drug incorp- 
oration   on   the   thermal   properties   of   the    organogels 
were   studied  by  DSC.  DSC  thermograms   for  the  second 
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Table 2. EFV equilibrium concentration in sunflower oil at 37 ± 1°C as a fonction of time. 
Equilibrium lime (h) 24 48 72 Median value* 
EFV concentration (mg/g oil) 82.47 ± 2.18 79.14 ± 3.49 79.78± 0.65 80.02 
*The median of ail measured values from 24 to 72 h because we cannot see differences among concentrations al different limes, the differences being 
smaller than standard deviations. 
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The thermal point of technical-grade 12-HSA is roughly 76 °C 
with a melting enthalpy of 182J/g35. 12-HSA/sunflower organo- 
gels display the following melting characteristics: as gelator 
concentration is increased, so does the melting enthalpy and the 
onset of melting, i.e. the gel melts at a higher temperature. For 
example, a 2wt% HSA sunflower oil gel has a Tm of approxi- 
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mately 57 °C, against 75 °C for a 20 wt% HSA. It is perhaps 
appropriate to remember that the main goal of this study is the 
optimization of a structured organogel matrix in which EFV could 
be solubilized to control its delivery in the GI tract after oral 
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administration . Thus, the best formulation for EFV-loaded 
organogels should take into  account the melting temperature of 
these systems. In fact, organogels being thermoreversible, they 
should guarantee both the thermal stability and solid-like behavior 
40 45 50 55 60 65 70 75 80 at  a  temperature  higher  than  or  equal  to  the  human  body 
(B) 1.2 
1.0 
0.8 
0.6 
u::: 
-:;; 
G1     0.4 
:I: 
0.2 
0.0 
Temperature (°C) 
40 45 50 55 60 65 70 75 80 
Temperature (°C) 
temperature, and even higher than 40 °C to combine environ- 
mental and storage aspects. All fractions of 12-HSA used in this 
study to produce sunflower oil gels are able to lead to a structured 
network of 12-HSA since the onset for melting is approximately 
48 °C for the lower gelator concentration (2 wt%). 
Besides the gelator and its concentration, the effect of the drug 
on the gel structures should be an important parameter to be taken 
into account when developing organogels for drug delivery 
purposes. In previous studies reported in the literature, the drug 
was mostly suspended in the gel medium and had a little or no 
impact on the structures of the drug-loaded gels, which possessed 
nearly identical physical properties with blank gels15-17• In other 
cases, although no impact was observed on the gelation tempera- 
ture, the presence of some dissolved drug in the gel apparently 
shortened the time of phase inversion while raising drug 
content36.
The effect of the drug incorporation in the thermal transition 
temperatures of the organogels was also studied by DSC. EFV 
was incorporated (30 mg/g0rganogel  or 60 mg/g0rganogeJ  in 12-HSA/ 
Figure 2. DSC second-heating for gelled sunflower oil over the range of 
12-HSA compositions from 2% to  30wt%. Melting (A)  and 
Crystallization (B). 
heating-cooling cycle of the organogels without EFV (Samples 
01-09) are shown in Figure 2(a) and (b), respectively. The 
position of  the melting and the crystallization peaks shifts to 
higher temperatures as the concentration of 12-HSA is 
increased and they become broader and shallower at low 
concentrations of 12-HSA as shown in the bottom curves in 
Figure 2(a) (melting) and in the top curves in Figure 2(b) 
(crystallization). As expected, the organogels were thermo- 
reversible as identical thermal parameters were obtained  over 
the two melting/crystallization  cycles (data not shown). 
Table 3 shows the thermal parameters that describe the 
crystallization and melting behavior of organogels over the range 
of compositions from 2% to 30% (w/w) HSA. Tm(onset)> Tm and 
Tm(enctset) are the temperatures at the beginning, peak and end of 
the melting endotherm, respectively. Tc(onset) • Tc  and  Tc(endset)  are 
the temperatures at the beginning, peak and end of the crystal- 
lization exotherm, respectively. AHm and AHc are the melting and 
crystallization enthalpies, respectively, determined by integrating 
the area of each peak, melting and crystallization  respectively. 
sunflower oil gels containing different gelator concentrations (5%, 
10%, 20% and 30wt%). The DSC thermograms for the second 
heating-cooling cycle of EFV-loaded organogels formed with 
20%wt HSA are shown in Figure 3(a) and (b). The same trend was 
systematically seen for the whole gelator concentrations studied. 
The temperatures and heats of melting  (i.e. Tm and AHm) and 
crystallization  (Tc and AHc ) are reported in Table 3. 
The organogel melting enthalpy (AHm ) combines at least two 
distinct energetic contributions: (l) the melting enthalpy of the 
fibers (which should be more or Jess constant and independent of 
the solvent used if the fibers comprise pure gelator molecules 
organized in a similar and regular structure) and (2) the enthalpy 
of dissolution of the gelator in the solvent phase, which is related 
to the molecular affinity between the two species and should 
depend on the solvent used37'38. A decrease of the melting 
enthalpy could be taken as a sign of some re-arrangements in the 
microstructure and/or packing of the 12-HSA molecules occur- 
ring in the presence of the dissolved drug in the oil. However, the 
data shown in Table 3 suggest that the introduction of EFV in the 
gelling system did not result in evident changes on AHm or AHc of 
the formulations, but apparently reduced the thermal transition 
temperatures (Tm, Tc) by a few degrees while raising drug content. 
This is quite visualized for low gelator concentrations, the 
differences decreased when the HSA fraction increased, both Tm 
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Table 3. Thermal parameters obtained from the melting and crystallization thermograms of organogel with different concentrations of 12-HSA in 
sunflower oil, neat and loaded with EFV. 
Organogel composition 
and conditions of preparation Thermal properties measured by DSC 
Melting (Tm)* Crystallization  (Tc)* 
*Standard errors in brackets.
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and Tc are almost constant and only fonction of the gelator 
amount. A similar effect in onset temperatures was reported for 
soy organogel with different gelators: myristic, palmitic,  stearic 
and  arachidic  acids39. 
The onset of Tc is the last point associated with the solution 
state and the onset of Tm is the last point of the gel state. Anyway, 
the peak melting Tm and onset of crystallization temperatures of 
the gels increased as 12-HSA concentrations increased, whatever 
the gel studied, in the presence and absence of drug. Both thermal 
parameters  scaled in a logarithmic fashion in relation  to the  12- 
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HSA concentration  (Figure 4). The sol-gel transition  is some- 
times interpreted as dissolution or melting  of the "crystal " 
gelling molecules. In  this sense, the solubility of "crystals 
gelling" corresponds to the concentration of gelling agent in an 
ideal solution at a given temperature by the following Equation 
(9), called Schroeder-van Laar equation37•40•41 .
-ôHm 
(B) 1.2 
.,, 
c 
L1nC =--+ constant e 
R.Tm 
(9) 
w 
1.0 lêi 0.8 
:i: 0.60 i;::: 
--20wt% (08) 
.............20wt% (OEFV3)  
..
 
------ 20wt% (OEFV7) 
Where R is the universal gas constant and /'<;.Hm corresponds to the 
melting enthalpy apparent (sol-gel) of the pure gelling and C its 
molar concentration in the gel. According to this equation, a plot 
of L111 C versus 1/ Tm should be  a straight line. This linear 
dependency is confirmed in Figure 5. The melting and crystal- 
lization enthalpies likewise increased  in a linear manner with  an 
increase of the 12-HSA concentration (Figure 6). Similar 
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Figure 3. DSC second-heating  for gelled  12-HSA (20wt%) - sunflower 
oil loaded with EFV (30 mg/gorganogel or 60 mg/gorganogeÙ· Melting (A) 
and  Crystallization  (B). 
To clarify the mechanism of drug release from organogels, the 
weight loss and the amount of drug released were measured as a 
fonction of time. Experimental data plotted in Figure 7 highlights 
an initial slow release during the first hour, during which probably 
the drug diffuses slowly, followed by a second step characterized 
by a faster release. This faster release could be attributed to the 
onset of an erosion phenomenon, which makes the entrapped drug 
Sample 
HSA 
fraction Sunflower EFV Onset Peak Endset ôHm Onset Peak Endset ôHc 
ID (w/w) oil (w/w) (mg/goranoe1) (oC) (OC) (OC) (J/g) (°C) (OC) (°C) (J/g) 
01 0.02 0.98 48.3 (0.9) 56.6 (0.7) 61.4 (0.8) 0.75 (0.1) 54.0 (0.4) 51.0 (0.4) 43.6 (0.6) -0.54 (0.1)
02 0.04 0.96 53.9 (0.1) 61.5 (0.1) 67.7 (0.4) 0.90 (0.1) 57.7 (0.2) 55.0 (0.5) 49.6 (0.6) -0.80 (0.1)
03 0.05 0.95 55.5 (0.4) 66.9 (0.1) 70.7 (0.1) 4.5 (0.1) 63.7 (0.1) 62.2 (0.1) 59.2 (0.2) -5.2 (0.5) 
04 0.06 0.94 55.01 (0.4) 67.3 (0.3) 72.2 (0.4) 7.5 (0.1) 65.4 (0.2) 63.6 (0.1) 57.5 (1.5) -8.l (0.3) 
05 0.08 0.92 59.9 (0.9) 69.1 (0.4) 72.8 (0.2) 8.4 (1.1) 66.0 (0.1) 64.5 (0.1) 61.3 (0.5) -9.3 (0.1) 
06 0.10 0.90 64.5 (0.1) 71.8 (0.5) 74.4 (0.4) 12.l (0.9) 68.6 (0.1) 65.4 (0.5) 62.7 (2.2)  -13.5 (0.1) 
07 0.15 0.85 66.2 (0.8) 72.2 (0.2) 75.2 (0.7) 16.3 (0.7) 68.5 (0.2) 67.6 (0.1) 66.l (0.1)  -15.9 (0.1) 
08 0.20 0.80 72.3 (2.5) 75.3 (0.2) 77.05 (0.8) 29.6 (1.7) 70.2 (0.1) 68.8 (0.1) 67.5 (0.1)   -26.3 (0.1) 
09 0.30 0.70 74.2 (2.1) 77.4 (1.1) 78.6 (0.8) 41.2 (2.1) 71.0 (0.16) 70.5 (0.1) 68.7 (0.1)   -41.2 (0.3) 
OEFVI 0.05 0.95 30 55.2 (6.5) 62.5 (0.4) 70.8 (3.0) 5.1 (0.1) 61.0 (0.4) 58.8 (0.1) 55.5 (1.2) -4.8 (0.2) 
OEFV2 0.10 0.90 30 60.2 (0.4) 69.7 (0.6) 73.2 (0.3) 1 1.0 (0.2) 66.6 (0.1) 64.2 (0.4) 60.2 (0.7)  -10.1 (0.9) 
OEFV3 0.20 0.80 30 68.4 (1.0) 74.3 (1.1) 76.2 (0.6) 28.5 (1.1) 68.9 (0.3) 67.2 (0.1) 64.9 (0.2)   -27.7 (0.1) 
OEFV4 0.30 0.70 30 72.8 (2.5) 75.6 (0.3) 77.1 (0.2) 41.4 ( 1.5) 70.3 (0.1) 69.6 (0.1) 68.0 (0.1) -39.0 (0.5) 
OEFV5 0.05 0.95 60 50.9 (5.9) 58.0 (2.6) 61.8 (5.1) 5.7 (0.4) 56.0 (0.8) 52.0 (1.5) 47.4 (0.2) -5.0 (0.3) 
OEFY6 0.10 0.90 60 59.2 (0.2) 69.4 (1.1) 72.0 (0.3) 13.7 (1.0) 62.6 (0.1) 61.1 (0.6) 59.1 (0.6) -13.9 (0.1) 
OEFY7 0.20 0.80 60 70.0 (4.4) 73.6 (1 .0) 75.01 (0.3) 27.6 (1 .2) 67.1 (0.1) 65.2 (0.1) 64.6 (0.6) -28.3 (0.1) 
OEFV 8 0.30 0.70 60 72.0 (2.8) 74.8 (0.1) 76.6 (0.1) 40.4 (1.4) 69.7 (0.4) 68.2 (0.1) 66.7 (0.2) -38.8 (0.3) 
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Figure 4. Transition phase diagrams of organogels in different 12-HSA 
concentrations made without active pharmaceutical ingredient, with 
30mg/g and 60mg/g of Efavirenz. Blank symbols correspond to 
crystallization and black symbols correspond to melting. Means with 
error bars for two experiments (n =2) are shown. 
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Figure 6. Enthalpy of melting and crystallization of 12-HSA calculated 
from DSC peak area for 12-HSA series (organogels without active 
pharmaceutical ingredient and with 30 or 60mg/g of Efavirenz). Blank 
symbols correspond to crystallization and black symbols correspond to 
melting. Means with error bars for two experiments (n = 2) are shown. 
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fluid. The corresponding organogel erosion percents were 4 and 
12%, respectively. lt was also observed that the same organogels 
when formed at 5 °C eroded more easily (7 and 22% mass losses 
in gastric and intestinal conditions, respectively), although 
minor differences were observed on the amounts of drug 
released (24 and 34%), compared to those at 25 °C. 
In summary, the data presented here evidenced that both erosion 
and drug diffusion from the 12-HSA sunflower organogel are 
dependent on the matrix network (directly correlated to HSA 
concentration and temperature  of gel formation) and slightly 
affected by the EFV presence, especially at low concentration of 
HSA. Therefore, the more  structured the system the lower should 
be the matrix erosion, yielding to a lower drug release as a final 
result. More structured gels were obtained with the higher gelator 
2.85 2.90 2.95 3.00 3.05 
1000/Tm, K'1 
Figure 5. Representation of Schroeder-van Laar equation for the analysis 
of the influence of gelling agent concentration on the sol-gel transition 
temperature. Means with error bars for two experiments (n =2) are 
shown. 
more available. Combined drug diffusion and erosion may 
contribute to a faster release than erosion alone16.
The data shown in Figure 7 include the influence of four 
different parameters: gelator concentration (5 or 20 wt% HSA), 
temperature of gel formation (5 °C or 25 °C), and composition of 
the release media (pH 1.2 containing pepsin or pH 6.8 containing 
pancreatin) to simulate the GI tract. 
At the end of 8h of release, the mass lost (erosion) and the 
amount of drug released were more pronounced for organogels 
less concentrated in 12-HSA (5 wt%) formed at lower temperature 
(5 °C). In fact, organogels containing 5 wt% HSA (OEFVl) 
formed at 5 °C released 34% of EFV under simulated gastric 
conditions against 51% in simulated intestinal fluid. The corres- 
ponding organogel erosion percents were 25 and 41%, respect- 
ively. The temperature of gel formation influenced the amount of 
drug released and the organogel mass Joss. lncreasing the 
temperature of organogel formation to 25 °C led to an increased 
drug release (36% of EFV released in gastric and 45% in intestinal 
conditions; 27 and 39% of organogel mass Joss, respectively). 
In tum, organogels formed at 25 °C, loaded with 20 wt% 12- 
HSA (OEFV7) provided the smaller amounts of drug released 
and mass losses. They released approximately 24% of EFV under 
simulated gastric conditions against 32% in simulated intestinal 
concentration (20 wt% HSA) and the higher temperature of gel 
formation (25 °C). Both erosion and drug diffusion from more 
structured gels were less affected by the pH of the medium. These 
findings are also in agreement with the few works found in the 
literature related to drug delivery from organogels in simulated 
gastric  and intestinal test  solutions 15-17. 
Release profiles from the cylindrical organogels 
Dependent  models (curve fitting ) 
ln a general manner, the drug release from organogels may 
involve processes of diffusion, erosion or drug dissolution 16•17.
Diffusion and erosion are expected to be the processes controlling 
drug release from the organogels since EFV at the concentrations 
tested, is completely dissolved within the organogels, as expected 
from the measured solubility data and confirmed by DSC studies. 
The drug is then immediately  available  for diffusion. 
A large number of models (both empirical and mechanistic 
mathematical models) have been proposed to describe drug release 
mainly for polymer matrices characterized by a 3D network. Even 
though organogels have different structures, the models already 
proposed for more investigated polymeric carriers can be useful to 
fit experimental values to compare the release profiles obtained 
from different formulation (gelator concentration,  EFV  loading) 
and conditions (gel formation temperature)  studied here. 
The in vitro drug release data from the different organogels 
contaimng EFV were evaluated kinetically using the 
Korshmeyer-Peppas, Weibull and Hixson-Crowell models 
[Equations (2-4), Table 1]. Korsmeyer-Peppas mode!is expected 
to be valid only up to 60% cumulative drug release, so the data 
for  analysis  were  restricted  to  this  range.  The  coefficient  of 
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Figure 7. Weight Joss and release studies of organogels containing EFV at 37 °C. (a, c) Simulated gastric solution at pH 1.2 inclucling pepsin 800 U/L 
enzyme activity; (b, d) Simulated intestinal solution at pH 6.8 including pancreatin 1750 U/L protease activity. Means with error bars for two 
experiments (n = 2) are shown. 
determination (R2), root-mean-square error (RMSE) and Akaike's 
information criterion (AIC) values of these models were 
determined for evaluation of accuracy and prediction ability of 
these models using KinetDS 3.0 rev. 2010 software (Krakow, 
Poland). The result of the curve fitting into varions mathematical 
models is given in Table 4. The best fitting of models was based 
on goodness of fit, i.e. the highest coefficient  of  determination 
(R2) (doser to unity) and lowest  RMSE  and  AIC  values 
(definition in Table  1). 
From the obtained  results, it is observed that for all formula- 
tions the drug release mechanism is best described by Korsmeyer- 
Peppas model. This model is a semi-empirical mode!, relating 
exponentially the drug release to the elapsed time. Tt is used to 
analyze the release of pharmaceutical polymeric dosage forms, 
when the release mechanism is not well known or when more than 
one type of release phenomena  could be involved43.
The release exponent (n) is used in order to characterize different 
release mechanism. Ifthe n value is 0.5 or Jess, the release mechanism 
follows Fickian diffusion. Higher values of n (0.5 <n < 1) correspond 
to a non-Fickian model denominated anomalous transport  The 
drug release follows Zero-order drug release or Case-II transport if the 
n value is 1. For the values of n higher than 1, the mechanism of drug 
release is regarded as super Case-II transport, describing the influence 
of polymeric hydration and swelling on drug release for polymeric and 
swellable systems, and which can be related to matrix erosion for non- 
swellable systems. 
The values of diffusional exponent (n) determined from 
Korsmeyer-Peppas model ranged from 0.81 to 1.39 (Table 4) 
for all organogels loaded with EFV  (Fl-Fl6, refer Table 5 for 
formulation code description), indicating that the drug release 
from these systems followed the super case-II transport mechan- 
ism. However, the n value determined from this mode! for 
Reference (when EFV-60 mg/g0;1 is dissolved in non-gelled oil) is 
0.30 (Fl7, Table 4), denoting a Fickian  diffusion  mechanism. 
In conclusion, the release mechanism from organogels loaded 
with EFV is different from the diffusion mechanism obtained with 
simple oil formulations. From organogels, EFV probably diffuses 
through an outer gel layer that erodes, releasing oil droplets 
containing dissolved EFV into the aqueous medium. This 
conclusion is supported by the visual observation of the cylin- 
drical organogels before and after release in the test solutions. 
The photographs shown in Figure 8 were taken at the end of the 
erosion/release studies. It is clearly visible that the organogels 
undergo changes in thickness (decrease in diameter) mainly for 
organogels containing 5 wt% HSA, while the capsule length 
remained essentially unchanged. These findings evidence erosion 
occurring at the organogel surface (Figure 8) depending on the 
gelator concentration. 
The results from the evaluation of drug release mechanism 
using varions kinetic models confirmed the experimental obser- 
vations that both erosion and drug diffusion mechanisms take 
place, depending on the matrix network . 
Table 4. Results of curve fitting of the in vitro release data from different cylindrical organogels containing EFV. 
Formulation code (Table 5) 
Model-dependent method Kinetic parnmeters FI F2 F3 F4 F9 FlO Fi l Fl2 
Test solution: gastric solution (H 1.2) al 37 °C comprising pepsin 
R 0.9992 0.9999 0.9993 0.9999 0.9993 0.9997 0.9534 0.9998 
RMSE 1.2990 0.8705 l.8703 0.2703 l.2988 l.2349 2.6259 1.3810 
Korshmeyer-Peppas AIC 21.28 15.68 26.38 -0.69 21.28 20.57 31.14 22.14 
K 4.33 3.67 4.25 2.90 4.33 5.84 4.82 4.64 
n 1.02 0.98 0.93 1.05 1.02 0.82 0.96 0.81 
DR (%)4h 17.81 14.28 15.51 12.45 17.81 18.18 18.28 14.21 
R2 0.9990 0.9998 0.9992 0.9999 0.9990 0.9997 0.9520 0.9998 
Weibull RMSE 2.5639 1.0580 2.0647 0.6355 2.5639 1.5196 11.019 1.3133 
AIC 30.80 18.41 27.71 11.27 30.69 23.48 51.22 21.43 
R2 0.8024 0.7844 0.7692 0.7854 0.8024 0.7306 0.7625 0.7186 
Hixson-Crowell RMSE 7.5353 5.8859 6.8725 4.5060 7.5354 7.8429 10.248 6.101 
AIC 45.89 42.44 4.46 38.70 45.89 46.46 50.20 42.94 
Model-independent method DE 17.68 14.36 15.57 12.65 17.68 17.54 17.83 13.92 
Number of time points 7 7 7 7 7 7 7 7 
Test solution: intestinal solution (pH 6.8) at 37 °C comprising pancreatin 
Formulation code (Table 5) 
 Model-dependent   method Pararneters F5 F6 F7 F8 F13 F14 F I S Fl6 F17 
Table 5. Comparison of EFV-loaded organogel release profiles using the 
independent mode! values of dissolution efficiency DE (done using one- 
way [ANOVA] followed by Tukey's test). 
*Values represent the mean of two independent determinations. Same letters 
at the same colurnn indicate that there is no statistical difference (p <0.05). 
lndependent model 
Dissolution efficiency (DE) results are shown in Table 5. The 
analysis of variance (ANOVA) revealed a statistical difference 
(p <0.05)  between   the  formulations.  Differences  in  the  DE 
pH 6.8 including pancreatin 1750 U/L protease activity. (A) 20 wt% HSA 
and (B) 5 wt% HSA. Both organogels were loaded with EFV (60mg/g). A 
calibrated vernier cal iper was used for diameter and thickness evaluation 
of the gel capsules. 
data may be related to the release profiles since factors such as 
12-HSA concentration, drug loading, gel formation temperature 
and pH of the release medium may influence the release of the 
drug molecule from the organogels. 
R2 0.9989 0.9999 0.9993 0.9992 0.9997 0.9998 0.9998 0.9997 0.9975 
Korshmeyer-Peppas RMSE 1.0503 l.2482 1.5821 0.7897 1.2178 1.5781 1.6493 1.5383 3.4737 
AIC 18.3 2.07 24.04 14.32 20.38 24.08 24.63 23.65 24.45 
K 5.48 4.52 7.82 3.37 9.01 4.10 4.21 1.83 29.20 
n 1.02 0.89 0.65 1.07 0.85 0.99 1.05 1.39 0.30 
DR (%)4h 22.55 15.46 19.22 14.94 29.24 16.16 18.03 12.63 44.00 
R2 0.9999 0.9998 0.9994 0.9987 0.9999 0.9998 0.9997 0.9995 0.9980 
Weibull RMSE 1.1189 1.2339 1.5218 l.3811 0.9910 1.6369 2.057 3.4710 3.251 
AIC 19.19 20.56 2.35 22.14 17.49 24.52 27.72 35.04 23.84 
Rz 0.7726 0.7573 0.6457 0.7931 0.7228 0.7665 0.7890 0.8352 0.4353 
Hixson-Crowell RMSE 8.199 6.6980 8.0967 5.4566 11.380 6.1924 6.9713 3.8616 21.05 
AIC 47.08 44.25 46.90 41.38 53.67 43.15 44.81 36.54 42.51 
Model-independent method DE 22.86 15.33 18.04 15.20 28.64 16.18 18.44 13.95 40.74 
Number of time points 7 7 7 7 7 7 7 7 5 
Dissolution 
Formulation Formation EFV 
  
efficiency, DE 
code temperature mg HSA% pH mean (n =2)* 
Fl7 (oil formulation) 25 60 0 6.8 40.38" 
Fl4 5 60 5 6.8 30_97•.b 
F13 5 30 5 6.8 29_07•.b 
FS 25 30 5 6.8 22.86a,b 
F9 5 30 5 1.2 21.46•-b 
FIS 5 30 20 6.8 19.29•.b 
F7 25 30 20 6.8 18.04b 
FI 25 30 5 1.2 17.68b 
Fll 5 30 20 1.2 17.43b 
FIO 5 60 5 1.2 17.43b 
F3 25 30 20 1.2 15.57b 
F8 25 60 20 6.8 15.53b 
F6 25 60 5 6.8 15.33b 
F16 5 60 20 6.8 14.46b 
F2 25 60 5 1.2 14.36b 
Fl2 5 60 20 1.2 14.17b Figure 8. 12-HSA sunflower oil gel formed in gelatin capsules (size #OO) 
F4 25 60 20 1.2 12.65b removed after 8 h of incubation into simulated intestinal solution at 37 °C, 
Figure 9. SEM image of organogel beads produced by prilling process. 
600 1200 1800 2400 3000 
Wavenumbers, cm·' 
Figure 1O. Raman spectra and mapping for EFV-loaded organogel beads. 
To evaluate the difference among the 17 formulations, a post 
hoc Tukey test was performed on the results of ANOVA. With the 
application of the Tukey test it was possible to observe that, with a 
level of significance of 5%, DE of formulations Fl, F2, F3, F4, 
F6, F7, F8, FlO, Fll, F12 and F16 were equal and significantly 
smaller than the DE found for the formulation F17. Moreover, Fl7 
is not significantly different  from F5, F9, Fl3, F14  and  F15 
(p >0.05), which are not significantly different from one other. 
From these results, it could be concluded that the drug release 
was delayed by the gelled oil as already discussed, i.e. an oil- 
structured system is expected to present lower drug release rate. 
However, the different parameters studied such as the gelator 
concentration, the drug loading, the temperature of organogel 
formation and even the pH of the release media showed no 
significant difference on DE. 
 
Organogel beads for drug delivery purposes 
Beads characterization 
Size and shape. Figure 9 reveals that the organogel beads consist 
of large micron-scale beads, spherical in shape and very uniform 
in diameter {610 ± 5 µm). 
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Table 6. Results of curve fitting of the in vitro release data from organogel beads containing EFV. 
Test conditions: media at 37 °C containing 1wt% SDS with changing pH values (2 h at pH 1.2 and then 8 h at pH 6.8), without enzyme 
Model-dependent method 
Best mode!criteria Higuchi Hixson-Crowell Korsmeyer-Peppas Weibull 
R2 0.9750 0.8672 0.9983 0.9985 
RMSE 3.1759 7.9909 1.5272 1.9161 
AJC 
Parameters of the Korsmeyer-Peppas mode![Equation (2)] 
61.55 83.70 31 .39 
k (h") =26.72 ± 4.34 
n =0.62 ± 0.03 
54.52 
Dissolution  efficiency (DE, %) 
Model-independent method 
56.38 (number of time points = 13) 
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40% during the first 2 h under simulated gastric condition s (pH 
1.2). Despite an increase in the EFY solubility at pH 6.845, drug 
dissolution exhibited a slow release reaching 80% after 4 h of 
immersion into the simulated intestinal fluid. 
The data obtained during the release test were examined 
according to Korsmeyer-Peppas, Weibull, Hixson-Crowell and 
Higuchi equations [Equations (2-5), respectively, Table l]. The 
coefficient of determination (R2), root-mean-square error (RMSE) 
and Akaike's information criterion (AlC) values of these models 
were determined for evaluation of accuracy and prediction ability 
of these models using KinetDS 3.0 rev. 2010 software. The result 
of the curve fitting into various mathemati cal models is given in 
Table 6. Figure 10 also confirms the correlation of the EFV 
release profile with the theoretical profile predicted by these 
model s (see fitting curves). The best fitting was based on 
goodness of fit, i.e. the highest coefficient of determination (R2; 
Incubation time, h 
Figure 11. Release amount of EFV from the organogel beads containing 
20%wt 12-HSA as gelling agent during the release test at 37 °C (2 h in pH 
1.2, 8 h in pH 6.8). Means with error bars for three experiments (n = 3) 
are shown. 
Raman mapping. The Raman spectra of the individual compo- 
nents (HSA, sunflower oil and organogel beads) are compared in 
Figure 10. The Raman spectrum of 12-HSA displays a strong peak 
at around 2850-2900cm- 1 (C-H), peaks at 1440cm-1 (CH2) and 
two peaks around 1068-1135 cm-1 characteristics of C-0 
stretching bands. In turn, the characteristic peaks are identified 
in the Raman spectrum of the sunflower oil: at 1660cm-1 (C =C 
stretching bands) and the peaks at 1306 and 1272cm-1 ( =C-H 
deformation), already reported in the literature44. For the Raman 
spectrum of pure EFV, the CF3 stretching modes have been 
assigned at 1146cm-I, with a typical C =0 stretching bands at 
1791cm-1, one distinguishing intensive band at 2250cm- 1
assigned to C C stretching bands, which was not evident in the 
other gel components. 
The pure component Raman spectrum of 12-HSA could not be 
separated from that of sunflower oil using cluster analysis due to 
the homogeneous (molecular) dispersion of EFV within the 
organogel. Comparison of the Raman spectra of the samples 
revealed that, except for the EFV vibrational bands at 2250 cm-I,
there were no distinguishable vibrations bands. EFV was found 
uniformly distributed within the organogel. 
Release studies from organogel beads 
Figure 11 shows the cumulative amount of EFV release profiles 
from organogel beads comprising 20wt% of 12-HSA and loaded 
with 60mg/g of EFV. The organogel beads exhibited a slow 
dissolution  profile with  80% of the drug being released  after 8 h, 
closer to unity) and lowest RMSE and AlC values (Table 1). From 
the obtained results, it is observed that the drug release 
mechanism is also best described by Korsmeyer-Peppas model. 
The release exponent n calculated from Korsmeyer-Peppas mode! 
for predicting drug release mechanism was 0.62, corresponding to 
a non-Fickian mode! denominated anomalous transport, revealing 
that the EFV release is strongly influenced by the size of the 
organogel system. For the organogel beads an anomalous 
transport is the main release mechanism, whereas for cylindrical 
organogels (larger size) erosion and diffusion are the mechanisms 
controlling the release. The 3D-fibrillar network with 12-HSA as 
gelator is well documented in the literature and already observed 
in some of our previous works46-49. The driving force of 
controlled release is the entanglement of the network which 
represents a physical barrier to the diffusion of the entrapped oil 
containing the dissolved drug. Sorne interaction between EFV and 
12-HSA could delay the free EFY diffusion through the 12-HSA 
network. However, it was not detected in this study by the Raman 
mapping of the organogel beads. 
Conclusions 
This study underlines the interest of gelling sunflower oil with 12- 
HSA for the controlled release of a hydrophobie drug like EFV. 
With organogels of different shapes and sizes, exposed to different 
release conditions, it could be demonstrated that the drug release 
was controlled mainly by diffusion with a minor participation of 
erosion in absence of enzymes, or controlled by more than one 
process, a coupling of diffusion and erosion mechanisms, the later 
accelerated by enzymatic activities. 
Based on the drug release kinetics and mechanism models, 
EFV release from organogels could be described by the 
Korsmeyer-Peppas mode!with the highest coefficient of deter- 
mination and lowest RMSE and AIC values. The release exponent 
(n) allows highlighting  the different EFV release mechanisms 
with sunflower oil-based delivery systems: drug diffusion- 
controlled (sunflower oil, n = 0.30), anomalous transport  (orga-
nogel beads, n =0.62) and super Case-II transport (cylindrical 
organogels 0.81<n <1.39). Even though further data will be 
necessary to investigate EFV release k:inetics in the 12-HSA 
sunflower oil  gel more deeply, the obtained results have &bown 
that  is possible  to modify  the  drug release  from the  oil phase  by 
gelling the system. 
Furthermore, prilling is a useful and simple technique to 
prepare organogel beads with spherical shape and narrow size 
distribution. The beads could be applied fur the manufacture of 
multiparticulate dosage furms where a suitable controlled release 
rate could be designed to takc advantage of beads properties. The 
multiparticulate nature of beads as a dosage form (filled into
capsules) can offer important pharmacological  and technological 
advantages over conventional single-unit solid dosage forms. 
Further optimization of formulation wi11 be required before 
moving onto any in vivo studies. 
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